Development of antimicrobial resistance due to the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)

Detalhes bibliográficos
Autor(a) principal: Goulart, Débora Brito
Data de Publicação: 2021
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Research, Society and Development
Texto Completo: https://rsdjournal.org/index.php/rsd/article/view/24207
Resumo: Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) is a new coronavirus identified in 2019. This disease, which may cause a serious respiratory infection, has been designated an international public health emergency and is being treated with several types of antivirals, antibiotics, and antifungals. While society works hard to combat the coronavirus disease 2019 (COVID-19) pandemic, it is equally vital to be prepared for the outbreak’s notorious effects on the development of antimicrobial resistance (AMR). Antibiotic misuse and overuse are predicted to have serious ramifications for antibiotic stewardship programs and AMR management worldwide. Importantly, the global influence on the creation of novel antimicrobial resistance is uncertain due to a paucity of data on antimicrobial usage during the COVID-19 pandemic. The current pandemic might be a useful tool for depicting the spread of antimicrobial resistance and underlining the difficulties in managing the issue once it has emerged. This review aims to assess available data on bacterial infections in coronavirus-infected patients and to offer insight into the development of AMR in the face of the current public health issue.
id UNIFEI_92866978ea7846d0a5a430c049e5b494
oai_identifier_str oai:ojs.pkp.sfu.ca:article/24207
network_acronym_str UNIFEI
network_name_str Research, Society and Development
repository_id_str
spelling Development of antimicrobial resistance due to the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)Desenvolvimiento de resistencia a los antimicrobianos debido al Síndrome Respiratorio Agudo Grave Coronavirus 2 (SARS-CoV-2)Desenvolvimento de resistência antimicrobiana devido ao Coronavírus da Síndrome Respiratória Aguda Grave 2 (SARS-CoV-2)Severe Acute Respiratory Syndrome Coronavirus 2COVID-19PandemicPublic healthAntibioticsBacteriaAntimicrobial resistanceBacterial infections.Síndrome Respiratorio Agudo Grave Coronavirus 2COVID-19PandemiaSalud publicaAntibióticosBactériaResistencia a los antimicrobianosInfecciones bacterianas. Coronavírus da Síndrome Respiratória Aguda Grave 2COVID-19PandemiaSaúde públicaAntibióticosBactériaResistência antimicrobianaInfecções bacterianas.Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) is a new coronavirus identified in 2019. This disease, which may cause a serious respiratory infection, has been designated an international public health emergency and is being treated with several types of antivirals, antibiotics, and antifungals. While society works hard to combat the coronavirus disease 2019 (COVID-19) pandemic, it is equally vital to be prepared for the outbreak’s notorious effects on the development of antimicrobial resistance (AMR). Antibiotic misuse and overuse are predicted to have serious ramifications for antibiotic stewardship programs and AMR management worldwide. Importantly, the global influence on the creation of novel antimicrobial resistance is uncertain due to a paucity of data on antimicrobial usage during the COVID-19 pandemic. The current pandemic might be a useful tool for depicting the spread of antimicrobial resistance and underlining the difficulties in managing the issue once it has emerged. This review aims to assess available data on bacterial infections in coronavirus-infected patients and to offer insight into the development of AMR in the face of the current public health issue.Síndrome Respiratorio Agudo Grave Coronavirus 2 (SARS-CoV-2) es un nuevo coronavirus identificado en 2019. Esta enfermedad, que puede causar una infección respiratoria grave, ha sido designada como emergencia de salud pública internacional y está siendo tratada con varios tipos de antivirales, antibióticos y antifúngicos. Si bien el mundo trabaja arduamente para combatir y controlar la pandemia de la enfermedad del coronavirus 2019 (COVID-19), es igualmente fundamental estar preparado para los efectos devastadores de este brote en el desenvolvimiento de la resistencia a los antimicrobianos (AMR). Durante esta pandemia, se espera que el uso incorrecto y excesivo de antibióticos tenga graves consecuencias para los programas de administración de antibióticos y la gestión de la AMR en todo el mundo. Es importante destacar que la influencia global en la creación de una nueva resistencia a los antimicrobianos es incierta debido a la escasez de datos sobre el uso de antimicrobianos durante la pandemia de COVID-19. En el futuro, la pandemia actual podría ser una herramienta útil para describir la propagación de la resistencia a los antimicrobianos y subrayar las dificultades para manejar el problema una vez que ha surgido. Esta revisión tiene como objetivo evaluar los datos disponibles sobre infecciones bacterianas en pacientes infectados por coronavirus y ofrecer información sobre qué esperar con la AMR y el desenvolvimiento antimicrobiano frente al problema de salud pública actual.Coronavírus da Síndrome Respiratória Aguda Grave 2 (SARS-CoV-2) é um novo coronavírus identificado em 2019. Esta doença, que pode causar uma infecção respiratória grave, foi designada uma emergência internacional de saúde pública e está sendo tratada com vários tipos de antivirais, antibióticos e antifúngicos. Embora o mundo trabalhe para combater e controlar a pandemia da doença do coronavírus 2019 (COVID-19), é igualmente importante estarmos preparados para os efeitos devastadores desse surto no desenvolvimento da resistência antimicrobiana (AMR). Durante a atual pandemia, espera-se que o uso incorreto e excessivo de antibióticos tenha consequências graves nos programas de administração de antibióticos e gerenciamento de AMR em todo o mundo. É importante ressaltar que a influência global na criação de uma nova resistência antimicrobiana é incerta devido à escassez de dados sobre o uso de antimicrobianos durante a pandemia causada pelo SARS-CoV-2. No futuro, a atual pandemia pode ser uma ferramenta útil para descrever a propagação da resistência antimicrobiana e destacar as dificuldades em gerenciar o problema, uma vez que o mesmo tenha surgido. Esta revisão tem como objetivo avaliar os dados disponíveis sobre infecções bacterianas em pacientes infectados pelo novo coronavírus e oferecer uma visão sobre o que esperar da resistência antimicrobiana e do desenvolvimento de antimicrobianos em face do atual problema de saúde pública.Research, Society and Development2021-12-16info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://rsdjournal.org/index.php/rsd/article/view/2420710.33448/rsd-v10i16.24207Research, Society and Development; Vol. 10 No. 16; e479101624207Research, Society and Development; Vol. 10 Núm. 16; e479101624207Research, Society and Development; v. 10 n. 16; e4791016242072525-3409reponame:Research, Society and Developmentinstname:Universidade Federal de Itajubá (UNIFEI)instacron:UNIFEIenghttps://rsdjournal.org/index.php/rsd/article/view/24207/21132Copyright (c) 2021 Débora Brito Goularthttps://creativecommons.org/licenses/by/4.0info:eu-repo/semantics/openAccessGoulart, Débora Brito2021-12-20T11:03:07Zoai:ojs.pkp.sfu.ca:article/24207Revistahttps://rsdjournal.org/index.php/rsd/indexPUBhttps://rsdjournal.org/index.php/rsd/oairsd.articles@gmail.com2525-34092525-3409opendoar:2024-01-17T09:42:50.779238Research, Society and Development - Universidade Federal de Itajubá (UNIFEI)false
dc.title.none.fl_str_mv Development of antimicrobial resistance due to the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
Desenvolvimiento de resistencia a los antimicrobianos debido al Síndrome Respiratorio Agudo Grave Coronavirus 2 (SARS-CoV-2)
Desenvolvimento de resistência antimicrobiana devido ao Coronavírus da Síndrome Respiratória Aguda Grave 2 (SARS-CoV-2)
title Development of antimicrobial resistance due to the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
spellingShingle Development of antimicrobial resistance due to the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
Goulart, Débora Brito
Severe Acute Respiratory Syndrome Coronavirus 2
COVID-19
Pandemic
Public health
Antibiotics
Bacteria
Antimicrobial resistance
Bacterial infections.
Síndrome Respiratorio Agudo Grave Coronavirus 2
COVID-19
Pandemia
Salud publica
Antibióticos
Bactéria
Resistencia a los antimicrobianos
Infecciones bacterianas.
Coronavírus da Síndrome Respiratória Aguda Grave 2
COVID-19
Pandemia
Saúde pública
Antibióticos
Bactéria
Resistência antimicrobiana
Infecções bacterianas.
title_short Development of antimicrobial resistance due to the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
title_full Development of antimicrobial resistance due to the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
title_fullStr Development of antimicrobial resistance due to the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
title_full_unstemmed Development of antimicrobial resistance due to the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
title_sort Development of antimicrobial resistance due to the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
author Goulart, Débora Brito
author_facet Goulart, Débora Brito
author_role author
dc.contributor.author.fl_str_mv Goulart, Débora Brito
dc.subject.por.fl_str_mv Severe Acute Respiratory Syndrome Coronavirus 2
COVID-19
Pandemic
Public health
Antibiotics
Bacteria
Antimicrobial resistance
Bacterial infections.
Síndrome Respiratorio Agudo Grave Coronavirus 2
COVID-19
Pandemia
Salud publica
Antibióticos
Bactéria
Resistencia a los antimicrobianos
Infecciones bacterianas.
Coronavírus da Síndrome Respiratória Aguda Grave 2
COVID-19
Pandemia
Saúde pública
Antibióticos
Bactéria
Resistência antimicrobiana
Infecções bacterianas.
topic Severe Acute Respiratory Syndrome Coronavirus 2
COVID-19
Pandemic
Public health
Antibiotics
Bacteria
Antimicrobial resistance
Bacterial infections.
Síndrome Respiratorio Agudo Grave Coronavirus 2
COVID-19
Pandemia
Salud publica
Antibióticos
Bactéria
Resistencia a los antimicrobianos
Infecciones bacterianas.
Coronavírus da Síndrome Respiratória Aguda Grave 2
COVID-19
Pandemia
Saúde pública
Antibióticos
Bactéria
Resistência antimicrobiana
Infecções bacterianas.
description Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) is a new coronavirus identified in 2019. This disease, which may cause a serious respiratory infection, has been designated an international public health emergency and is being treated with several types of antivirals, antibiotics, and antifungals. While society works hard to combat the coronavirus disease 2019 (COVID-19) pandemic, it is equally vital to be prepared for the outbreak’s notorious effects on the development of antimicrobial resistance (AMR). Antibiotic misuse and overuse are predicted to have serious ramifications for antibiotic stewardship programs and AMR management worldwide. Importantly, the global influence on the creation of novel antimicrobial resistance is uncertain due to a paucity of data on antimicrobial usage during the COVID-19 pandemic. The current pandemic might be a useful tool for depicting the spread of antimicrobial resistance and underlining the difficulties in managing the issue once it has emerged. This review aims to assess available data on bacterial infections in coronavirus-infected patients and to offer insight into the development of AMR in the face of the current public health issue.
publishDate 2021
dc.date.none.fl_str_mv 2021-12-16
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv https://rsdjournal.org/index.php/rsd/article/view/24207
10.33448/rsd-v10i16.24207
url https://rsdjournal.org/index.php/rsd/article/view/24207
identifier_str_mv 10.33448/rsd-v10i16.24207
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv https://rsdjournal.org/index.php/rsd/article/view/24207/21132
dc.rights.driver.fl_str_mv Copyright (c) 2021 Débora Brito Goulart
https://creativecommons.org/licenses/by/4.0
info:eu-repo/semantics/openAccess
rights_invalid_str_mv Copyright (c) 2021 Débora Brito Goulart
https://creativecommons.org/licenses/by/4.0
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Research, Society and Development
publisher.none.fl_str_mv Research, Society and Development
dc.source.none.fl_str_mv Research, Society and Development; Vol. 10 No. 16; e479101624207
Research, Society and Development; Vol. 10 Núm. 16; e479101624207
Research, Society and Development; v. 10 n. 16; e479101624207
2525-3409
reponame:Research, Society and Development
instname:Universidade Federal de Itajubá (UNIFEI)
instacron:UNIFEI
instname_str Universidade Federal de Itajubá (UNIFEI)
instacron_str UNIFEI
institution UNIFEI
reponame_str Research, Society and Development
collection Research, Society and Development
repository.name.fl_str_mv Research, Society and Development - Universidade Federal de Itajubá (UNIFEI)
repository.mail.fl_str_mv rsd.articles@gmail.com
_version_ 1797052699575844864

Registros relacionados